抗流感药物市场迎变局:奥司他韦或暂停挂网,新药抢滩登陆

21世纪经济报道
17 Jun

21世纪经济报道记者李佳英广州报道昔日占据抗流感药物市场半壁江山的奥司他韦陷入风波。近日,浙江省医保局公布一则药品价格调整公示,包括Natco Pharma Limited、东阳光长江药业、成都倍特、普利制药、罗欣药业等企业生产的磷酸奥司他韦胶囊均面临价格调整或被暂停挂网。名单在列的“可威”品牌磷酸奥司他韦胶囊,是东阳光长江药业当家品种之一。虽未公布具体调价幅度,但浙江省医保局明确提及“涉及价格...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10